With numerous SARM1-targeting approaches already demonstrating efficacy in animal and cell models, including antisense oligonucleotides, small-molecule inhibitors, and DN-SARM1 constructs (82, 86–89), our discovery paves the way for testing these therapies for treating ADOA. This evidence concerns the gene SARM1 and autosomal dominant optic atrophy.